<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GATIFLOXACIN- gatifloxacin solution/ drops </strong><br>Pacific Pharma<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use gatifloxacin safely and effectively. See full prescribing information for gatifloxacin.<br>Gatifloxacin ophthalmic solution 0.5% <br>Initial U.S. Approval: 1999
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Gatifloxacin ophthalmic solution is a topical fluoroquinolone anti-infective indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:
 </p>
<p class="Highlighta"><span class="Italics">Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis</span> group*, <span class="Italics">Streptococcus oralis*, Streptococcus pneumoniae</span> </p>
<p class="Highlighta">*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. (<a href="#s1">1</a>)
 </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Patients 1 year of age or older:  Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7. (<a href="#s2">2</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">5 mL size bottle filled with 2.5 mL of gatifloxacin ophthalmic solution, 0.5%. (<a href="#s3">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None
  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Topical Ophthalmic Use Only (<a href="#s6">5.1</a>)
</li>
<li>Growth of Resistant Organisms with Prolonged Use (<a href="#s7">5.2</a>)
</li>
<li>Avoidance of Contact Lenses. Patients should not wear contact lenses if they have signs or symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with gatifloxacin (<a href="#s8">5.3</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions occurring in ≥ 1% of patients included worsening of <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>. (<a href="#s9">6</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
</div>
<div></div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1   Topical Ophthalmic Use Only
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Growth of Resistant Organisms with Prolonged Use
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Avoidance of Contact Lens Wear
</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience
</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS
</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers
</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use
</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use
</a></h2>
<h1><a href="#section-9" class="toc">11 DESCRIPTION
</a></h1>
<h1><a href="#section-10" class="toc">12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-10.1" class="toc">12.1  Mechanism of Action
</a></h2>
<h2><a href="#section-10.2" class="toc">12.3  Pharmacokinetics
</a></h2>
<h2><a href="#section-10.3" class="toc">12.4  Microbiology
</a></h2>
<h1><a href="#section-11" class="toc">13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-12" class="toc">14 CLINICAL STUDIES
</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-14.1" class="toc">17.1  Avoiding Contamination of the Product
</a></h2>
<h2><a href="#section-14.2" class="toc">17.2  Avoidance of Contact Lens Wear
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE
</h1>
<p class="First">Gatifloxacin ophthalmic solution 0.5% solution is indicated for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms:
</p>
<p><span class="Bold">Aerobic Gram-Positive Bacteria:<br></span><span class="Italics">Staphylococcus aureus<br>Staphylococcus epidermidis<br>Streptococcus mitis</span> group<span class="Italics">*<br>Streptococcus oralis*<br>Streptococcus pneumoniae</span></p>
<p><span class="Bold">Aerobic Gram-Negative Bacteria:<br></span><span class="Italics">Haemophilus influenzae</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION
</h1>
<p class="First">Patients 1 year of age or older:  Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7.
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">Five (5) mL bottle containing 2.5 mL of a 0.5% sterile topical ophthalmic solution.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS
</h1>
<p class="First">None
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-5.1"></a><p></p>
<h2>5.1   Topical Ophthalmic Use Only
</h2>
<p class="First">Gatifloxacin solution should not be introduced directly into the anterior chamber of the eye.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Growth of Resistant Organisms with Prolonged Use
</h2>
<p class="First">As with other anti-infectives, prolonged use of gatifloxacin ophthalmic solution 0.5% may result in overgrowth of nonsusceptible organisms, including fungi. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit lamp biomicroscopy and where appropriate, fluorescein staining.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Avoidance of Contact Lens Wear
</h2>
<p class="First">Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> or during the course of therapy with gatifloxacin (see PATIENT COUNSELING INFORMATION, <a href="#s30">17.2</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s9"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience
</h2>
<p class="First">Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
</p>
<p>In clinical studies with gatifloxacin, the most frequently reported adverse reactions occurring in ≥ 1% of patients in the gatifloxacin study population (N=717) were: worsening of the <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">dysgeusia</span>, and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.
</p>
<p>Additional adverse events reported with other formulations of gatifloxacin ophthalmic solution include <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">chemosis</span>, <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, <span class="product-label-link" type="condition" conceptid="4080696" conceptname="Discharge from eye">eye discharge</span>, <span class="product-label-link" type="condition" conceptid="374950" conceptname="Edema of eyelid">eyelid edema</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, increased <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, papillary <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, and reduced visual acuity.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s11"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS
</h1>
<p class="First">Specific drug interaction studies have not been conducted with gatifloxacin ophthalmic solution.
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s12"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s13"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category C
</p>
<p>Teratogenic Effects: There were no teratogenic effects observed in rats or rabbits following oral gatifloxacin doses up to 50 mg/kg/day (approximately 1000-fold higher than the maximum recommended ophthalmic dose). However, skeletal/craniofacial malformations or delayed ossification, atrial enlargement, and reduced fetal weight were observed in fetuses from rats given ≥150 mg/kg/day (approximately 3000-fold higher than the maximum recommended ophthalmic dose). In a perinatal/postnatal study, increased late post-implantation loss and neonatal/perinatal mortalities were observed at 200 mg/kg/day (approximately 4000-fold higher than the maximum recommended ophthalmic dose).
</p>
<p>Because there are no adequate and well-controlled studies in pregnant women, gatifloxacin solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s15"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers
</h2>
<p class="First">Gatifloxacin is excreted in the breast milk of rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when gatifloxacin  is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s16"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use
</h2>
<p class="First">The safety and effectiveness of gatifloxacin in infants below one year of age have not been established. Gatifloxacin has been demonstrated in clinical trials to be safe and effective for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> in pediatric patients one year or older (see CLINICAL STUDIES, <a href="#s25">14</a>).
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s17"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s18"></a><a name="section-9"></a><p></p>
<h1>11 DESCRIPTION
</h1>
<p class="First">Gatifloxacin sterile ophthalmic solution is an 8-methoxyfluoroquinolone anti-infective for the treatment of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Its chemical name is (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate. Its molecular formula is C<span class="Sub">19</span>H<span class="Sub">22</span>FN<span class="Sub">3</span>O<span class="Sub">4
</span><span class="Bold">·</span> 1½H<span class="Sub">2</span>O, and its molecular weight is 402.42. Its chemical structure is:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Chemical Structure
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dd6ac6b-877a-46c7-bbc8-c7119f341abe&amp;name=structuralformula.jpg">
</div>
<p>Gatifloxacin is a clear, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow, sterile, preserved aqueous solution with an <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of 260-330 mOsm/kg and a pH of 5.1-5.7.
</p>
<p>Gatifloxacin contains <span class="Bold">Active:</span> gatifloxacin 0.5% (5 mg/mL); <span class="Bold">Inactives:</span> benzalkonium chloride 0.005%; edetate disodium; purified water; and sodium chloride. May contain hydrochloric acid and/or sodium hydroxide to adjust pH.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s19"></a><a name="section-10"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s20"></a><a name="section-10.1"></a><p></p>
<h2>12.1  Mechanism of Action
</h2>
<p class="First">Gatifloxacin is a fluoroquinolone antibacterial (see CLINICAL PHARMACOLOGY, <a href="#s22">12.4</a>).
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s21"></a><a name="section-10.2"></a><p></p>
<h2>12.3  Pharmacokinetics
</h2>
<p class="First">Gatifloxacin ophthalmic solution 0.3% or 0.5% was administered to one eye of 6 healthy male subjects each in an escalated dosing regimen starting with a single 2 drop dose, then 2 drops 4 times daily for 7 days, and finally 2 drops 8 times daily for 3 days. At all time points, serum gatifloxacin levels were below the lower limit of quantification (5 ng/mL) in all subjects.
</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s22"></a><a name="section-10.3"></a><p></p>
<h2>12.4  Microbiology
</h2>
<p class="First">Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no cross-resistance between gatifloxacin and the aforementioned classes of antibiotics. Cross-resistance has been observed between systemic gatifloxacin and some other fluoroquinolones.
</p>
<p>Resistance to gatifloxacin <span class="Italics">in vitro</span> develops via multiple-step mutations. Resistance to gatifloxacin <span class="Italics">in vitro</span> occurs at a general frequency of 1 x 10<span class="Sup">-7</span> to 10<span class="Sup">-10</span>.
</p>
<p>Gatifloxacin has been shown to be active against most isolates of the following organisms both microbiologically and clinically, in conjunctival <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE, Section 1.
</p>
<p><span class="Bold">Aerobic Gram-Positive Bacteria:<br></span><span class="Italics">Staphylococcus aureus<br>Staphylococcus epidermidis<br>Streptococcus mitis</span> group<span class="Italics">*<br>Streptococcus oralis*<br>Streptococcus pneumoniae</span></p>
<p><span class="Bold">Aerobic Gram-Negative Bacteria:<br></span><span class="Italics">Haemophilus influenzae</span></p>
<p>*Efficacy for this organism was studied in fewer than 10 <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s23"></a><a name="section-11"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s24"></a><a name="section-11.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">There was no increase in neoplasms among B6C3F1 mice given gatifloxacin in the diet for 18 months at doses averaging 81 mg/kg/day in males and 90 mg/kg/day in females. These doses are approximately 1600-fold and 1800-fold higher, respectively, than the maximum recommended ophthalmic dose of 0.05 mg/kg/day in a 50 kg human.
</p>
<p>There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (900- and 2800-fold higher, respectively, than the maximum recommended ophthalmic dose). A statistically significant increase in the incidence of large granular lymphocyte (LGL) <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> was seen in males treated with a high dose of approximately 2000-fold higher than the maximum recommended ophthalmic dose. Fischer 344 rats have a high spontaneous background rate of LGL <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> and the incidence in high-dose males only slightly exceeded the historical control range established for this <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span>.
</p>
<p>In genetic toxicity tests, gatifloxacin was positive in 1 of 5 <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used in bacterial reverse mutation assays: <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA102. Gatifloxacin was positive in <span class="Italics">in vitro</span> mammalian cell mutation and chromosome aberration assays. Gatifloxacin was positive in <span class="Italics">in vitro</span> unscheduled DNA synthesis in rat hepatocytes but not human leukocytes. Gatifloxacin was negative in <span class="Italics">in vivo</span> micronucleus tests in mice, cytogenetics test in rats, and DNA repair test in rats. The findings may be due to the inhibitory effects of high concentrations on eukaryotic type II DNA topoisomerase.
</p>
<p>There were no adverse effects on fertility or reproduction in rats given gatifloxacin orally at doses up to 200 mg/kg/day (approximately 4000-fold higher than the maximum recommended ophthalmic dose for gatifloxacin).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s25"></a><a name="section-12"></a><p></p>
<h1>14 CLINICAL STUDIES
</h1>
<p class="First">In two randomized, double-masked, multicenter clinical trials, where patients 1-89 years of age were dosed for 5 days, gatifloxacin solution was clinically superior to its vehicle on day 6 in patients with <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and positive conjunctival cultures. Clinical outcomes for the trials demonstrated clinical success (resolution of <span class="product-label-link" type="condition" conceptid="377283" conceptname="Conjunctival hyperemia">conjunctival hyperaemia</span> and <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctival discharge</span>) of 58% (193/333) for the gatifloxacin-treated groups versus 45% (148/325) for the vehicle-treated groups. Microbiological outcomes for the same clinical trials demonstrated a statistically superior eradication rate for causative pathogens of 90% (301/333) for gatifloxacin versus 70% (228/325) for vehicle. Please note that microbiological eradication does not always correlate with clinical outcome in anti-infective trials.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s26"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">Gatifloxacin ophthalmic solution 0.5% is supplied sterile in a white, low density polyethylene (LDPE) bottle with a controlled dropper tip, and a tan, high impact polystyrene (HIPS) cap in the following size:
</p>
<p>2.5 mL in 5 mL bottle: NDC 60758-615-25
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s27"></a><a name="section-13.1"></a><p></p>
<p class="First"><span class="Bold">Storage:</span> Store at 15°-25°C (59°-77°F). Protect from freezing.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s28"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s29"></a><a name="section-14.1"></a><p></p>
<h2>17.1  Avoiding Contamination of the Product
</h2>
<p class="First">Patients should be instructed to avoid contaminating the applicator tip with material from the eye, fingers, or other source.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s30"></a><a name="section-14.2"></a><p></p>
<h2>17.2  Avoidance of Contact Lens Wear
</h2>
<p class="First">Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.
</p>
<p>© 2014 Allergan, Inc.<br>Irvine, CA 92612, U.S.A.<br>® marks owned by Allergan, Inc.<br>Licensed from Kyorin Pharmaceuticals Co., Ltd.<br>Patented. See: www.allergan.com/products/patent_notices<br>Made in the U.S.A.
</p>
<p><a name="f02"></a><img alt="Pacificpharma Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dd6ac6b-877a-46c7-bbc8-c7119f341abe&amp;name=pacificpharma-logo.jpg"></p>
<p>72366PY10
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s31"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - 2.5 mL Carton Label</span></p>
<p><span class="Bold">PACIFIC<br>PHARMA</span><span class="Sup">®</span></p>
<p>NDC 60758-615-25
</p>
<p><span class="Bold">GATIFLOXACIN</span></p>
<p>ophthalmic
</p>
<p>solution 0.5%
</p>
<p><span class="Bold">2.5 mL</span></p>
<p>sterile
</p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel - 2.5 mL Carton Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3dd6ac6b-877a-46c7-bbc8-c7119f341abe&amp;name=carton.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GATIFLOXACIN 		
					</strong><br><span class="contentTableReg">gatifloxacin solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:60758-615</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>gatifloxacin</strong> (gatifloxacin anhydrous) </td>
<td class="formItem">gatifloxacin</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:60758-615-25</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">2.5 mL in 1 BOTTLE, DROPPER; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA authorized generic</td>
<td class="formItem">NDA022548</td>
<td class="formItem">04/15/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Pacific Pharma
							(877645267)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Allergan, Inc.</td>
<td class="formItem"></td>
<td class="formItem">362898611</td>
<td class="formItem">MANUFACTURE(60758-615)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>87e00c7c-dcc1-45aa-8b71-c42f459f49d2</div>
<div>Set id: 3dd6ac6b-877a-46c7-bbc8-c7119f341abe</div>
<div>Version: 1</div>
<div>Effective Time: 20150415</div>
</div>
</div> <div class="DistributorName">Pacific Pharma</div></p>
</body></html>
